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Abstract
There are no published studies examining the effects of N-acetylcysteine (NAC) administration on the non-enzymatic defence 
systems in humans exposed to lead. In view of this, it was decided to measure the levels of uric acid (UA), albumin, bilirubin 
and alpha-tocopherol before and after treatment with NAC. An estimation was also made of the degree of oxidative stress 
by measuring the ferric reducing ability of plasma (FRAP), the levels of conjugated dienes (CD) and lipid hydroperoxides 
(LHP). Male employees who worked with lead were randomized into two groups. The first group included workers who 
were not administered any drugs (n=49), while the second group (n=122) consisted of workers who were treated with 
NAC at three different doses (200 mg, 400 mg and 800 mg) for 12 weeks. The administration of NAC (400 mg, 800 mg) 
resulted in significant decreases in the LHP levels. Similarly, a strong tendency toward lower levels of CD was observed in 
the same groups. The UA levels were significantly lower only in the group receiving the 200 mg dose of NAC. However, the 
alpha-tocopherol levels were significantly elevated after treatment with NAC (400 mg, 800 mg). NAC administration did 
not significantly affect the levels of bilirubin and albumin, but a tendency toward higher values was observed for FRAP. 
NAC reduced the extent of lipid peroxidation in a dose-dependent manner. Elevated concentrations of alpha-tocopherol 
may have enhanced the beneficial effects of NAC. Treatment with NAC may contribute to the restoration of non-enzymatic 
antioxidant reserves when administered to lead-exposed workers.
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INTRODUCTION
N-acetylcysteine (NAC) is a low molecular weight compound 
administered to neutralize the deleterious effects of free 
radicals. NAC raises the intracellular concentration of 
cysteine and hence of reduced glutathione (GSH), which acts 
as an important endogenous antioxidant. Moreover, NAC 
has direct scavenging properties in vitro against hydroxyl 
radicals and hypochlorous acid [1]. NAC is rapidly absorbed 
following oral dosing and reaches its peak concentrations in 
the blood within 1 hour. After passing through the intestine 
and liver, NAC is transformed into a variety of metabolites. 
Consequently, NAC has been shown to have multiple 
therapeutic benefits [2].
NAC has been used in clinical practice since the 1960s 
when it was introduced as a mucolytic agent for the treatment 
of respiratory diseases, such as chronic bronchitis and cystic 
fibrosis. Since the late 1970s, NAC has been administered 
as an antidote for the therapy of acute acetaminophen 
intoxication [3]. Currently, NAC is being studied for use 
in many disorders, such as chronic obstructive pulmonary 
disease (COPD), contrast-induced nephropathy, influenza, 
idiopathic pulmonary fibrosis, polycystic ovary syndrome 
[4] and lead poisoning [5].
Lead induces a broad range of physiological and biochemical 
dysfunctions [5]. Exposure to this metal affects many 
body systems and leads to hematopoietic, cardiovascular, 
immunological, renal and hepatic dysfunction. The kidney 
is particularly susceptible to lead toxicity, resulting in 
nephropathy, proximal tubular damage, glomerular sclerosis, 
and lowered glomerular filtration rate. In addition, the 
effects of lead toxicity on the cardiovascular system include 
hypertension, coronary heart disease, stroke and peripheral 
arterial disease [6,7].
Recent studies have demonstrated the potential of lead to 
induce oxidative stress. The evidence also indicates that lead 
acts through multiple mechanisms. First, lead has a high 
affinity for thiol groups, and it forms thiolates with the thiol 
groups of cysteine. Lead also forms less stable complexes 
with other amino acid side chains. Lead exposure can also 
result in the depletion of glutathione and the inhibition 
of several enzymes having functional thiol groups, such 
as delta-aminolevulinic acid dehydratase [8]. Second, lead 
generates reactive oxygen species (ROS), such as hydrogen 
peroxide, superoxide radical, singlet oxygen and hydroxyl 
radical [9]. ROS attack all cellular macromolecules. The 
polyunsaturated fatty acid residues of phospholipids are 
extremely sensitive to oxidation and undergo a process of 
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peroxidation [7]. This results in the formation of conjugated 
dienes, lipid hydroperoxides and degradation products, such 
as malondialdehyde (MDA) [10].
Studies on lead-exposed rats have shown that the 
administration of NAC decreased the levels of MDA 
and oxidized glutathione (GSSG); it was also effective in 
restoring reduced glutathione (GSH) in the blood [11]. There 
are apparently no published studies on the effects of NAC 
administration in humans exposed to lead. Taking into 
account that NAC has a high toxicity threshold and a long 
history of safe clinical use, the decision was made to evaluate 
the effects of NAC administration in lead-exposed workers.
The accumulated data about the interactions between lead 
and the non-enzymatic defence systems are fragmentary and 
inconsistent. In view of this, it was decided to simultaneously 
measure the levels of uric acid, albumin, bilirubin and alpha-
tocopherol before and after NAC treatment. The degree of 
oxidative stress and lipid peroxidation, were also estimated 
by determining the ferric reducing ability of plasma, the 
levels of  conjugated dienes and the quantities of lipid 
hydroperoxides.
MATERIALS AND METHOD
Study population. The examined population included male 
employees in the southern region of Poland who worked with 
lead. Their mean age was 42.5 ± 8.66 years and had been 
exposed to lead for an average of 18.1 ± 9.46 years. To determine 
the degree of lead exposure, the blood concentrations of lead 
(PbB) and zinc-protoporphyrin (ZPP) were measured. These 
measurements were taken, on average, every 3 months during 
the 2 years of observation. The mean blood concentrations 
of lead (PbBmean) and zinc-protoporphyrin (ZPPmean) were 
calculated from the collected data.
Inclusion criteria were defined as follows: occupational 
exposure to lead (PbBmean > 20 μg/dl and ZPPmean > 2.5 μg/g 
Hb), a negative physical examination (no symptoms and signs 
of any disease, such as elevated blood pressure, abnormal 
pulse, auscultatory signs, elevated body temperature etc.), 
and no past or present history of any of chronic disease. 
Exclusion criteria were exhibition of any contraindications 
to the treatment with NAC.
The examined population (n=171) was randomized into 
2 groups. The first group included workers who were not 
administered any antioxidants, drugs, vitamins or dietary 
supplements (reference group, n=49). The second group 
consisted of 3 subgroups of workers who were treated orally 
with NAC (Fluimucil®, Medagro) at 3 different doses for 12 
weeks (n=122). The subdivision of the second group was 
according to the NAC dose. The first subgroup included 
40 workers who were administered 200 mg of NAC once a 
day (NAC 200 subgroup), the second subgroup included 44 
workers who were administered 200 mg of NAC twice a day 
(NAC 400 subgroup), and the third subgroup included 38 
workers who were administered 400 mg of NAC twice a day 
(NAC 800 subgroup).
Blood from all the examined workers was collected at 
the beginning of the study and after 12 weeks of treatment 
or observation. The 2 blood samples from each participant 
were examined for the levels of uric acid (UA), albumin, 
bilirubin in serum and alpha-tocopherol in the plasma. The 
ferric reducing ability of the plasma (FRAP), the levels of 
conjugated dienes (CD) in plasma and the levels of lipid 
hydroperoxides (LHP) in the serum were also determined.
The experimental protocol was reviewed and approved by 
the Bioethics Committee of the Medical University of Silesia 
in Katowice (No. NN-6501–36/I/06).
Laboratory procedures. Whole blood was used for the analysis 
of the lead (PbB) and zinc-protoporphyrin (ZPP) levels.
Graphite furnace atomic absorption spectrophotometry 
(Unicam 929 and 939OZ Atomic Absorption Spectrometers 
with GF90 and GF90Z Graphite Furnaces) was used to 
measure the PbB levels. Data were displayed as μg/dl.
The ZPP concentration was measured by means of the 
Aviv Biomedical haematofluorometer (Model 206). In this 
method, light is filtered by means of an interference filter 
transmitting at a wavelength of 415 nm. The excitation light is 
focused on a drop of blood. The emitted light passes through 
a narrow band interference filter transmitting at a wavelength 
of 596 nm. The instrument measures the ratio of ZPP as a 
fluorescent substance to the absorption of the light in the 
sample (haemoglobin). The results were expressed as μg ZPP 
per gram of haemoglobin (μg/g Hb).
The concentration of CD was measured according to the 
method by Corongiu et al. [12] using a spectrophotometer 
(Shimadzu, Model A160). The method by Södergren et al. [13] 
was used to measure the concentration of LHP. The results 
were expressed as μmol/l.
FRAP levels were determined by the Benzie and Strain 
method [14] using the biochemical analyzer EM 280 (Emapol, 
Poland). The data were shown as μmol/l. The level of alpha-
tocopherol was measured by the Shearer method [15], 
incorporating high-performance liquid chromatography 
with a Spherimage 80 ODS2 column and a UV/Vis detector 
(Knauer, Germany). EuroChrom 2000 software (Knauer, 
Germany) was used to perform calculations. The results 
were shown as μmol/l. The concentrations of uric acid 
(UA), albumin and bilirubin were measured using the A25 
biochemical analyzer (BioSystems, Spain), according to the 
manufacturer’s instructions. The results for UA and bilirubin 
were expressed as μmol/l, while those for albumin expressed 
as g/l.
Statistical analysis. All statistical analyses were performed 
using Statistica 9.1 PL software. The statistical methods 
included the mean and standard deviation. The Shapiro-
Wilk’s test was used to verify normality, whereas Levene’s 
test was used to verify the homogeneity of the variances. 
Statistical comparisons between groups used Student’s 
t-test, a t-test with separate variance estimates or the Mann-
Whitney U test. Dependent variables were analyzed using 
Student’s t-test and the Wilcoxon rank-sum test. An alpha 
value of p<0.05 was considered statistically significant.
RESULTS
No significant differences in age, years of work, body mass 
index (BMI) or smoking habits were observed between the 
examined groups and the subgroups. There were also no 
differences in the PbBmean and the ZPPmean levels calculated 
before the treatment (Tab. 1).
The administration of NAC resulted in significant decreases 
in the LHP levels in the NAC 400 and NAC 800 subgroups 
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compared to the reference group. Similarly, a strong tendency 
towards lower values of the CD levels was observed in the 
same subgroups (Tab. 2).
UA levels after NAC administration were significantly lower 
only in the NAC 200 subgroup compared to the reference 
group. However, the concentrations of alpha-tocopherol were 
significantly elevated after the treatment with NAC in the 
NAC 400 and NAC 800 subgroups compared to the levels at 
the beginning of the study. Only in the NAC 800 subgroup 
was the observed increase significant when compared to the 
reference group (Tab. 3).
Treatment with NAC did not significantly affect the 
bilirubin or albumin levels, while there was a tendency 
toward higher FRAP values (Tab. 3).
DISCUSSION
Thee presented study demonstrates that administration 
of higher doses of NAC (400 and 800 mg) significantly 
decreased serum levels of lipid hydroperoxides in workers 
chronically exposed to lead, while the uric acid was decreased 
only after dose of 200 mg of NAC. Additionally we showed 
elevated alpha-tocopherol plasma levels following NAC 
administration.
Both LHP and CD levels have been reported to increase 
due to the action of lead ions. Increased LHP concentrations 
were observed in the liver and serum of rats treated with lead 
acetate [16,17]. However, Adonaylo and Oteiza [18] observed 
elevated CD levels when investigating the effect of lead on 
lipid oxidation in liposomes. In the presented study, it is 
shown that after NAC administration the levels of LHP 
did not change in the NAC 200 subgroup, but decreased 
significantly by 26% and 50% in the NAC 400 and NAC 
800 subgroups, respectively. These results suggest that NAC 
reduced lipid peroxidation in a dose-dependent manner. 
The effect of treatment with NAC on the CD concentrations 
was less significant. However, a tendency toward lower CD 
levels was observed. In vivo and in vitro studies in animals 
are in accordance with the presented study because many 
authors have observed that NAC administration significantly 
decreased MDA levels, which served as a lipid peroxidation 
biomarker [11]. The potency of NAC to reduce lipid 
peroxidation intensity in lead exposure may be due to its 
ability to scavenge free radicals and stimulate synthesis of 
glutathione which serves as a major thiol antioxidant of the 
human body [1]. Besides, it is possible that NAC reduces the 
interactions of lead with thiol groups of antioxidant enzymes 
or even chelates lead ions, although the chelating properties 
of NAC are controversial.
Alpha-tocopherol possesses the highest biological 
activity in the group of 8 naturally-occurring compounds 
collectively referred to as vitamin E. Alpha-tocopherol 
limits the propagation of lipid peroxidation and is required 
to protect biological membranes and lipoproteins from 
oxidative stress [19]. Rendón-Ramirez et al. [20] reported 
Table 1. Epidemiologic parameters, the mean blood lead level (PbBmean) and the mean level of zinc protoporphyrin in blood (ZPPmean) in a Pb-exposed 
population before treatment with N-acetylcysteine (NAC) and observation in the reference group. p value – in comparison to reference group
Reference group
n=49
NAC-total
n=122
NAC-200
n=40
NAC-400
n=44
NAC-800
n=38
mean SD mean SD p value mean SD p value mean SD p value mean SD p value
age 40.9 8.25 42.5 8.66 0.288 40.6 8.49 0.848 43.1 8.81 0.218 43.7 8.55 0.131
years of work 15.2 8.57 18.1 9.46 0.067 17.1 9.71 0.325 18.4 9.50 0.088 18.7 9.33 0.074
BMI (kg/m2) 27.1 3.21 27.0 3.61 0.902 27.3 3.63 0.766 26.4 3.56 0.364 27.34 3.66 0.707
smoking habits 55% 52% 0.756 55% 0.992 52% 0.787 50% 0.641
PbBmean (μg/dl) 42.9 6.3  43.8 7.4 0.449 41.7 7.41 0.400 44.9 7.61 0.159 44.73 6.77 0.195
ZPPmean (μg/g Hb) 7.96 4.00 8.04 3.33 0.896 7.63 3.54 0.686 8.34 3.20 0.616 8.11 3.29 0.847
Table 2. Oxidative stress intensity measured as the level of conjugated dienes (CD) in plasma and lipid hydroperoxides (LHP) in serum in a Pb-exposed 
population before and after 3 months of treatment with N-acetylcysteine (NAC) and observation in the reference group. p value – in comparison to 
reference group, p value* comparison between after and before treatment
Reference group
n=49
NAC-total
n=122
NAC-200
n=40
NAC-400
n=44
NAC-800
n=38
mean SD mean SD p value mean SD p value mean SD p value mean SD p value
CD concentration
(µmol/l) before
145 24.1 154 29.6 0.076 151 21.2 0.260 157 33.1 0.192 153 33.2 0.203
CD concentration
(µmol/l) after
152 27.4 145 25.5 0.096 148 22.2 0.485 145 28.4 0.239 140 25.2 0.043
p-value* 0.168 0.014 0.176 0.064 0.270
Δ CD-p concentration  7.10 37.6 -8.76 37.7 0.008    -2.20 16.5 0.049 -11.5 44.8 0.026 -12.5 44.4 0.029
LPH concentration
(µmol/l) before
20.1  7.26 21.1 11.1 0.657 19.3  7.26 0.718 21.7  11.49 0.529  21.6 13.0 0.596
LPH concentration
(µmol/l) after
21.4 11.8 15.3  7.60 0.002 19.9  7.64 0.612 16.1  7.22 0.025  10.8  5.55 <0.001
p-value* 0.736 <0.001 0.330 <0.001 <0.001
Δ LPH -s  1.38  8.45 -5.79  9.51 0.001  0.64  6.56 0.742    -5.55  7.38 0.001 -10.9 11.2 <0.001
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that vitamin E administration to rat erythrocytes treated 
with lead decreased the oxidative damage to lipids and 
prevented the inhibition of delta-aminolevulinic dehydratase 
activity. Consistently, Patra et al. [21] observed decreased 
MDA levels in the livers and brains of rats administered 
lead and alpha-tocopherol compared to rats administered 
only lead. However, a study by Ergurhan-Ilhan et al. [22] 
showed that even low exposure to lead (PbB = 7.9 ± 5.2 μg/
dl) may result in decreased levels of serum alpha-tocopherol 
in humans. In contrast, Prokopowicz et al. [23] indicated 
that occupational lead-exposure is negatively correlated 
with the concentration of gamma-tocopherol rather than 
with alpha-tocopherol. However, Caylak et al. [24] observed 
decreased levels of vitamin E in rats orally exposed to lead 
acetate. In this report, NAC administration did not restore 
the vitamin E levels. In contrast, the results of the presented 
study indicate that treatment with NAC increases alpha-
tocopherol concentrations in lead-exposed workers in a dose-
dependent manner. Concentrations of alpha-tocopherol in 
the NAC 400 and NAC 800 subgroups increased by 16% 
and 30%, respectively. These elevations of alpha-tocopherol 
may contribute to the simultaneously observed decreased 
levels of LHP.
Bilirubin is an end product in heme metabolism and is 
known to have toxic effects at high concentrations. In humans, 
under physiological conditions, bilirubin serves as a strong 
antioxidant, which acts synergically with alpha-tocopherol 
to protect lipids from oxidative damage [25]. Noriega et al. 
[26] showed that bilirubin administration decreases lipid 
peroxidation and increases glutathione levels and the activity 
of antioxidant enzymes in rats. Conversely, elevated plasma 
bilirubin levels in rats treated with lead acetate have been 
reported in several studies [27]. The current findings indicate 
that NAC administration did not significantly influence 
bilirubin levels in lead-exposed workers. Because bilirubin 
acts as an antioxidant, the normalization of its levels after 
NAC administration would not be desirable.
Nephropathy occurs most often at high levels of lead 
exposure (>60 μg/dl). In contrast, damage to the kidney at 
lower lead levels has been reported (~10 μg/dl). There are 
2 types of renal functional abnormalities resulting from 
lead-exposure, acute nephropathy and chronic nephropathy. 
In acute nephropathy, a tubular transport mechanism is 
impaired and abnormal excretion of glucose, phosphates 
and amino acids are observed (Fanconi-like syndrome). 
In contrast, chronic nephropathy is much more severe 
Table 3. Non-enzymatic antioxidant concentrations, uric acid (UA), albumin, bilirubin in serum, alpha-tocopherol in plasma and ferric reducing ability 
of plasma (FRAP), in a Pb-exposed population before and after 3 months of treatment with N-acetylcysteine (NAC) and observation in the reference 
group. p value – in comparison to reference group, p value* comparison between after and before treatment
Reference group
n=49
NAC-total
n=122
NAC-200
n=40
NAC-400
n=44
NAC-800
n=38
mean SD mean SD p value mean SD p value mean SD p value mean SD p value
FRAP
(µmol/l) before
514 72.2 524 119 0.646 492 75.0 0.220 535 148 0.442 536 105 0.294
FRAP
(µmol/l) after
517 72.5 558 116 0.040 534 73.8 0.368 553 94.5 0.060 585 160 0.022
p-value* 0.653 0.018 0.026 0.269 0.322
Δ FRAP-R 3.15 92.6 34.5 156 0.245 41.9 83.6 0.081 18.7 157 0.593 48.3 198 0.210
UA concentration
(µmol/l) before
324 85.3 342 100 0.285 339 57.0 0.373 345 118 0.329 342 116 0.426
UA concentration
(µmol/l) after
330 79.3 314 68.6 0.204 301 61.6 0.067 330 71.8 0.990 310 70.1 0.222
p-value* 0.464 <0.001 <0.001 0.381 0.189
Δ UA   5.24 92.6 -27.7 89.6 0.016 -37.3 64.3 0.016 -15.3 86.4 0.273 -32.0 114 0.096
α-tocopherol conc. (µmol/l) 
before
18.9   6.77 20.8   8.80 0.189 17.8   6.64 0.456 21.5 9.57 0.154 23.0   9.14 0.024
α-tocopherol conc. (µmol/l) 
after
19.7   8.95 25.2   9.74 0.001 20.4   9.34 0.732 24.9   7.70 0.006 29.9 10.1 <0.001
p-value* 0.759 <0.001 0.246 0.029 <0.001
Δ α-tocopferol   0.79   9.50   4.33 10.1 0.040   2.66   9.08 0.384   3.41   9.96 0.222   6.89 11.0 0.009
Bilirubin concentration
(µmol/l) before
14.7   6.09 16.0 10.9 0.472 14.9   9.11 0.919 16.5 11.8 0.379 16.5 11.8 0.377
Bilirubin concentration
(µmol/l) after
16.1   8.31 16.1   8.36 0.957 13.8   8.39 0.079 17.4   7.87 0.463 16.8   8.61 0.724
p-value* 0.321 0.344 0.514 0.141 0.433
Δ bilirubin   1.46   9.05   0.10 11.8 0.495      -1.02   9.66 0.235   0.94 12.3 0.826   0.29 13.2 0.643
Albumin concentration (g/l) 
before
46.1   3.26 43.7   3.92 <0.001 45.7   3.07 0.566 42.8   3.56 <0.001 42.6   4.42 <0.001
Albumin concentration (g/l) 
after
44.7   3.87 43.6   4.24 0.121 45.9   3.59 0.163 42.9   3.79 0.029 42.0   4.49 0.005
p-value* 0.031 0.433 0.959 0.955 0.180
Δ Albumin     -1.33   4.15 -0.04   3.61 0.048   0.22   2.83 0.041   0.16   4.38 0.095 -0.58   3.33 0.383
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and is characterized by glomerular and tubulo-interstitial 
changes, which may cause renal breakdown, hypertension 
and hyperuricaemia [28].
A significant increase in the UA levels in lead-exposed 
workers with PbB = 29.1 μg/dl and PbB = 80.9 μg/dl was 
reported in studies by Khan et al. [7] and by Bener et al. 
[29], respectively. Positive correlations between blood lead 
levels and UA concentrations were also observed in humans 
by Hernández-Serrato et al. [30] and by Ehrlich et al. [31]. 
However, no association between blood lead and UA levels 
has been reported. Alternatively, Berrahal et al. [32] observed 
decreased UA levels in rats that were orally exposed to 
lead acetate. The authors of this study suggested that the 
hypouricaemia might occur because of decreased xanthine 
oxidase (XO) activity or due to lead-induced Fanconi-like 
renal tubular defects.
The decreased levels of UA, which were observed in the 
present study in the NAC 200 subgroup, and the tendencies 
toward lower UA levels in the remaining subgroups, suggest 
that NAC may exert protective effects on kidney function. 
Tayman et al. [33] reported decreased XO activity when 
investigating the effect of NAC on the development of 
necrotizing enterocolitis (NEC) in an experimental rat 
model. Therefore, it is possible that NAC could also inhibit 
XO activity in lead-exposed workers. In light of this, it is 
difficult to explain why 400 and 800 mg of NAC did not 
significantly affect the UA levels. Larger populations should 
be examined to verify the presented results. On the other 
hand, given that UA accounts for up to 60% antioxidative 
capacity of human blood [34], the limited influence of NAC 
administration on UA levels in the NAC 400 and NAC 800 
subgroups could be beneficial.
Albumin is synthesized in the liver and constitutes 
approximately 60% of the total protein in plasma. The 
cysteine thiol groups of albumin determine the redox status 
of plasma and act as ROS scavengers. Nonetheless, albumin 
sequesters redox-active metals and has been proposed to 
have a thioredoxin-dependent lipid hydroperoxide reductase 
activity in vitro [34, 35]. Koo et al. [36] observed decreased 
albumin mRNA levels in rat liver after the administration 
of lead nitrate. These results are supported by the studies 
of Mikhail et al. [37] and Khan et al. [7], who observed 
decreases in serum albumin and total protein levels in lead 
tank welders (PbB = 42.19 μg/dl) and lead-exposed industrial 
workers. However, Al-Neamy et al. [38] did not observe any 
significant changes in the levels of albumin and total protein 
in industrial workers exposed to lead (PbB = 77.5 μg/dl). 
Accumulated data indicate that the observed reductions in 
albumin and protein levels may be caused by the lead-induced 
inhibition of protein biosynthesis. The results of the presented 
study suggest that NAC administration would not be able to 
restore albumin to the levels preceding lead depletion.
The antioxidant and reducing potentials of biological fluids 
may be characterized by the FRAP values [14]. Although 
NAC administration was effective in decreasing the markers 
of lipid peroxidation, FRAP levels remained unchanged in 
the examined subgroups. A tendency toward higher levels 
compared to the reference group was only observed in 
the NAC 200 subgroup. The lack of significantly changed 
FRAP values may be due to the quick utilization of the thiol 
substrates provided by NAC, which maintained a reduced 
level of lipid peroxidation.
CONCLUSIONS
When administered to workers chronically exposed to 
lead, NAC reduced lipid peroxidation in a dose-dependent 
manner. The simultaneously elevated concentrations of 
alpha-tocopherol may enhance the beneficial effects of NAC. 
However, the influence of NAC on the levels of UA, bilirubin, 
albumin and FRAP seems to be limited. In conclusion, NAC, 
when administered to lead-exposed workers, may contribute 
to the restoration of non-enzymatic antioxidant reserves.
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